Department of Thoracic Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, 160 Pujian Road, Shanghai, 200127, China.
Department of Cardiothoracic Surgery, Changzheng Hospital, Naval Medical University, Shanghai, 200433, China.
BMC Cancer. 2022 Jul 20;22(1):801. doi: 10.1186/s12885-022-09908-3.
Log odds of positive lymph nodes (LODDS) is a novel lymph node (LN) descriptor that demonstrates promising prognostic value in many tumors. However, there is limited information regarding LODDS in patients with non-small cell lung cancer (NSCLC), especially those receiving neoadjuvant therapy followed by lung surgery.
A total of 2059 patients with NSCLC who received neoadjuvant therapy and surgery were identified from the Surveillance, Epidemiology, and End Results (SEER) database. We used the X-tile software to calculate the LODDS cutoff value. Kaplan-Meier survival analysis and receiver operating characteristic (ROC) curve analysis were performed to compare predictive values of the American Joint Committee on Cancer (AJCC) N staging descriptor and LODDS. Univariate and multivariate Cox regression and inverse probability of treatment weighting (IPTW) analyses were conducted to construct a model for predicting prognosis.
According to the survival analysis, LODDS had better differentiating ability than the N staging descriptor (log-rank test, P < 0.0001 vs. P = 0.031). The ROC curve demonstrated that the AUC of LODDS was significantly higher than that of the N staging descriptor in the 1-, 3-, and 5-year survival analyses (all P < 0.05). Univariate and multivariate Cox regression analyses showed that LODDS was an independent risk factor for patients with NSCLC receiving neoadjuvant therapy followed by surgery both before and after IPTW (all P < 0.001). A clinicopathological model with LODDS, age, sex, T stage, and radiotherapy could better predict prognosis.
Compared with the AJCC N staging descriptor, LODDS exhibited better predictive ability for patients with NSCLC receiving neoadjuvant therapy followed by surgery. A multivariate clinicopathological model with LODDS demonstrated a sound performance in predicting prognosis.
淋巴结阳性对数 odds(LODDS)是一种新的淋巴结(LN)描述符,在许多肿瘤中具有有前景的预后价值。然而,在接受新辅助治疗后接受肺手术的非小细胞肺癌(NSCLC)患者中,关于 LODDS 的信息有限,特别是在接受新辅助治疗后接受肺手术的 NSCLC 患者中。
从监测、流行病学和最终结果(SEER)数据库中确定了 2059 例接受新辅助治疗和手术的 NSCLC 患者。我们使用 X-tile 软件计算 LODDS 截断值。进行 Kaplan-Meier 生存分析和接收者操作特征(ROC)曲线分析,以比较 AJCC N 分期描述符和 LODDS 的预测值。进行单因素和多因素 Cox 回归以及逆概率治疗加权(IPTW)分析,以构建预测预后的模型。
根据生存分析,LODDS 的区分能力优于 N 分期描述符(对数秩检验,P<0.0001 与 P=0.031)。ROC 曲线表明,在 1 年、3 年和 5 年生存分析中,LODDS 的 AUC 均明显高于 N 分期描述符(均 P<0.05)。单因素和多因素 Cox 回归分析表明,LODDS 是接受新辅助治疗后接受手术的 NSCLC 患者的独立危险因素,无论是否进行 IPTW(均 P<0.001)。包含 LODDS、年龄、性别、T 分期和放疗的临床病理模型可以更好地预测预后。
与 AJCC N 分期描述符相比,LODDS 对接受新辅助治疗后接受手术的 NSCLC 患者具有更好的预测能力。包含 LODDS 的多因素临床病理模型在预测预后方面表现良好。